Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Exclusion Criteria

• •Patients who have received prior systemic treatment for metastatic melanoma.
• •Patients with known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
• •Patients with a known history of or known positive for Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA \[qualitative\] is detected). Patients with unknown history of Hepatitis B virus (HBV) or Hepatitis C virus (HCV) will require screening.
• •Patients with previously treated brain metastases may participate provided they are stable with no evidence of enlargement following radiation treatment and no acute radiation toxicity OR no evidence of enlargement at least 4 weeks prior to the first dose of study drug if untreated and are off systemic steroids for at least two weeks.
• •Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 4 months after the last dose of trial treatment.
• •Patients who previously had a severe hypersensitivity reaction to treatment with another mAb.
• •Patients with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. (Only patients on active treatment are ineligible).
• •Patients with a history of a malignancy (other than the disease under treatment in the study) within 5 years prior to first study drug administration.
• •Patients on any systemic corticosteroid therapy within one week before the planned date for first dose of treatment or on any other form of immunosuppressive medication.
• •Patients with an allergy to iodinated contrast media used for CT.
• •Patients with a known history of active TB (Bacillus Tuberculosis).
• •Patients with evidence of interstitial lung disease;
• •Patients with known history of, or any evidence of active, non-infectious pneumonitis